Medical News

RSS

SANUWAVE third quarter revenues increase to $278,000

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and nine months ended September 30, 2010 and provided a business update.

12 Nov 2010

Hana Biosciences announces financial results of third quarter 2010

Hana Biosciences, Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and nine months ended September 30, 2010, and provided a corporate update.

12 Nov 2010

Freedom Meditech announces clinical study results of I-SugarX non-invasive glucose monitoring system

Freedom Meditech, Inc., the developer of non-invasive, ophthalmic-based products to detect and manage diabetes, today announced results of a clinical study that showed a high correlation between low to high blood glucose levels and non-invasive glucose measurements in the eye in a live animal model.

12 Nov 2010

Nile third quarter net loss decreases to $1.8 million

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for therapeutics for cardiovascular disease, today announced its third quarter financial results for 2010.

12 Nov 2010

Neurologix third quarter net loss decreases to $2.3 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010.

12 Nov 2010

Denial is top reason for patients to delay treatment for skin cancer

If detected early, nonmelanoma skin cancers (primarily basal cell and squamous cell carcinomas, the two most common forms of skin cancer) can be easily treated. But when left untreated, these skin cancers can grow and even spread, causing considerably more harm than if they were treated upon initial detection. Now, a new study finds that denial is the top reason why patients delay seeking treatment for skin cancer and shows that this delay results in larger, more serious, skin cancers.

12 Nov 2010

MEDTOX Scientific board approves special one-time dividend

MEDTOX Scientific, Inc. today announced that its board of directors approved a special one-time cash dividend of $1.25 per share. The special dividend will be payable on December 1, 2010, to stockholders of record on November 22, 2010.

12 Nov 2010

Agilent fourth quarter revenues increase 35% to $1.58 billion

Agilent Technologies Inc. today reported revenues of $1.58 billion for the fourth fiscal quarter ended Oct. 31, 2010, 35 percent above one year ago, or 26 percent excluding the effects of the Varian acquisition and recent divestitures. Fourth-quarter GAAP net income was $232 million, or $0.66 per diluted share. Last year's fourth-quarter GAAP net income was $25 million, or $0.07 per share.

12 Nov 2010

Cortex third quarter net loss decreases to $528,000

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $528,000, or $0.01 per share, for the quarter ended September 30, 2010, compared with a net loss applicable to common stock of approximately $3,243,000 or $0.06 per share, for the prior year quarter.

12 Nov 2010

Abaxis releases new Piccolo reagent disc panel

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced the release of a new Piccolo® reagent disc panel called BioChemistry Panel Plus. This new reagent disc will be used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.

12 Nov 2010

IBEC researchers discover new group of interacting partners for myelin-associated receptors

It's known that the development of neuronal diseases such as multiple sclerosis and Alzheimer's disease is connected with the levels of myelin - an insulating substance around nerve fibres - in the body, although the actual causes of these conditions remain unknown. Now researchers at IBEC have discovered a new group of interacting partners for myelin-associated receptors, which could shed light on the significance of imbalanced production or modifications of the substance.

12 Nov 2010

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm Inc. today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO™ (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

12 Nov 2010

Targeted Genetics enters definitive agreements to acquire Biocontrol

Targeted Genetics Corporation, today announced that it has entered into definitive agreements related to the acquisition of Biocontrol Limited, or Biocontrol.

12 Nov 2010

VIMOVO granted marketing and pricing approval in the UK

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has been notified by AstraZeneca that marketing and pricing approval for VIMOVO™ (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets, has been granted in the United Kingdom (UK).

12 Nov 2010

EMS World Magazine announces winners of 2010 Top Innovation Awards

EMS World Magazine, the leading monthly publication for the emergency medical services market, has announced the winners of the 2010 Top Innovation Awards, which recognize the industry's most innovative products of the year. The winners were chosen by industry expert and EMS World Magazine Editorial Advisory Board Member Mike Smith, BS, MICP. The awards will be presented at the Texas EMS State Conference in Austin, TX, November 21-24.

12 Nov 2010

Amorfix second quarter net loss decreases to $25,728

Amorfix Life Sciences, a product development company focused on the development of diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the three and six months ended September 30, 2010.

12 Nov 2010

Spectrum Pharmaceuticals ranked #23 on Deloitte's Technology Fast 500

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it ranked #23 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growing during the period from 2005-2009. Spectrum Pharmaceuticals grew 6,490% during this period.

12 Nov 2010

CytomX awarded $488,000 as grant under QTDP Program

CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).

12 Nov 2010

Soligenix third quarter revenues increase to $861,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the third quarter of 2010.

12 Nov 2010

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the third quarter and the nine months ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

12 Nov 2010